Sinai-Trieman L, Salusky I B, Fine R N
Department of Pediatrics, University of California, Los Angeles Center for the Health Sciences.
J Pediatr. 1989 Apr;114(4 Pt 1):550-4. doi: 10.1016/s0022-3476(89)80692-4.
Five anemic, transfusion-dependent patients aged 12 to 18 years, who had end-stage renal disease (mean hematocrit value 22 +/- 0.31%) and were on a regimen of peritoneal dialysis, were treated with recombinant human erythropoietin (rHuEpo), which was self-administered at home by subcutaneous injections thrice weekly at an initial dosage of 150 U/kg. All patients had an increase in the reticulocyte count and hemoglobin concentration, and none required further transfusions. The hematocrit level rose to a mean of 33.04 +/- 1.86% within 3 weeks of rHuEpo therapy, and the dosage was adjusted to keep the hematocrit level between 32% and 38% indefinitely. Currently four of these patients require only one dose a week to sustain the hematocrit level. No antibodies to the rHuEpo were formed. Three patients had an exacerbation of hypertension, which required an adjustment in antihypertensive therapy. No other side effects were noted. The results demonstrate that rHuEpo is effective in correcting the anemia of end-stage renal disease, thereby eliminating the associated clinical symptoms and the need for further blood transfusions.
5名年龄在12至18岁之间、患有终末期肾病（平均血细胞比容值为22±0.31%）且正在接受腹膜透析治疗的贫血、依赖输血的患者，接受了重组人促红细胞生成素（rHuEpo）治疗，初始剂量为150 U/kg，由患者在家中自行皮下注射，每周3次。所有患者的网织红细胞计数和血红蛋白浓度均有所增加，且均无需进一步输血。在rHuEpo治疗3周内，血细胞比容水平平均升至33.04±1.86%，并调整剂量以使血细胞比容水平无限期维持在32%至38%之间。目前，这些患者中有4名仅需每周注射一剂就能维持血细胞比容水平。未形成针对rHuEpo的抗体。3名患者出现高血压加重，需要调整抗高血压治疗。未观察到其他副作用。结果表明，rHuEpo可有效纠正终末期肾病的贫血，从而消除相关临床症状以及进一步输血的需求。
